Nicholas E. Papadopoulos

1 ta ish

Melanoma Institute Australia

1. A randomized phase III trial of biochemotherapy versus interferon-α-2b for adjuvant therapy in patients at high risk for melanoma recurrence

   Kevin B. Kim, Sewa S. Legha, René González +18

   Maqola20092 iqtibos

   ABIABI:AkademIndex/2026.other.106252